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Abstract: Prostate cancer is the most common cancer in men and therefore represents a major problem
in public health.The aim of this study was to find and evaluate province-specific estimate of incidence
in males by age groups for prostate cancer in Golestan province, Iran. The data used in this study were
collected in a cancer registry program that was conducted by Health Deputy of Golestan province in
IRAN for a period of 1 year (2004). Prostate cancer data was identified and collected in the population
based cancer registries through the 18 Pathology Laboratories (where male populations referred to
these centers) and using a structured questionnaire, trained personnel conducted in-person interviews to
collect information on prostate cancer in Golestan province. Prostate cancer incidence among males in
Golestan province was 5.17/100000 in gerenal. But the highest rate (ASR: 215.87/100,000) among
males were showen to be in age 80-85. The incidence of prostate cancer in age 80-84 has risen sharply
and it was the lowest in age 50-54 (ASR: 5.18/100,000). According to this information Golestan
province harbor a rather incidence for prostate cancer (in age 80-84), comparable to the lower
incidence rate reported in the world. For the present time it can be said that prostate cancer in males
appear to be one of the most prevalent and serious type of cancer in Golestan province.
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At present, cancer is a serious public health
problem in many countries of the world, imposing a
large economical and psychological burden as well as
loss of life and productivity[1]. Lots of effort and money
have been put in the fields of clinical, epidemiological,
pharmacological, and biological research on cancer in
the recent decades. Cancer is the third most common
cause of death in Iran and annually 30000 of Iranian die
due to cancer[2]. It is estimated that more than 70000
new cases of cancer occur in the country and it is
estimated that the cancer incidence in next decade
suspected to be increased due to increase in elderly
population within the country [3]. Prostate cancer is the
second leading cause of male cancer death in most
industrialized countries [4].It is the most common
cancer diagnosed among men in the United States. In
2005, an estimated 232,090 new cases diagnosed and
30,350 men will die from prostate cancer in the United
States [5]. African-Americans have the highest reported
rates of prostate cancer in the world (With a worldwide
incidence of 25.3 per 100,000), with an age-adjusted
rate of 137 per 100,000, which is 60 times higher than
the reported incidence in Shanghai, China, where the
reported incidence is the lowest in the world (2 per
100,000)[6-7].The distribution of cancers vary
significantly from country to country all over the world.
The latest estimates of global cancer incidence show
that prostate cancer is the sixth most common cancer in 
the world, the third most common cancer in men, the
most common cancer in men in Europe, North America,
and some parts of Africa with half a million new cases 
[8-10]each year, almost 10% of all cancers in men .
Prostate cancer incidence is characterized by a very
large geographical variability. Asian countries have
much lower rates of occurrence of the disease than
North American, and north and western European 
countries, with southern European and South American
countries displaying an intermediate incidence rate[11].
Japanese and Chinese men are less likely to develop
prostate cancer [12]. The incidence of prostate cancer
was lowest among Asians (Japanese, 39/100 000 
person-years) and Chinese (28/100 000 person-
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years)[13]. Cancer registries are available in many
countries, but it is important to note that the degree of
accuracy may vary. In many countries cancer registries
have only recently been established and/or may not
cover the whole country, this may explain the low rates 
of cancer in some reports [14]. In Italy and Spain,
prostate cancer incidence, according to estimates in
2000, was ranked third (approximately 10% of all new
diagnosed cancers), while in France it was the most
common male cancer (approximately 19%) [15].This
study was a province-specific estimate of incidence by
age groups for prostate cancer in the year 2004.
MATERIALS AND METHODS
The data used in this study were collected in a
cancer registry that was conducted by Health Deputy of
Golestan province in IRAN for a period of 1 year
(2004). This article focuses on the male cancer registry.
Golestan province is located in north of Iran, in the
south east of Caspian Sea. The male cancer registry of
the Golestan province for different cancer was 409. The
collected data included population distribution by
gender (male) and age, divided into five-year intervals.
The age distribution was collected according to the
following age strata: 0-4, 5-9, 10-14, 15-19, 20-24, 25­
29, 30-34, 35-39, 40-44, 45-49, 50-54, 55-59, 60-64,
65-69, 70-74, 75-79, 80-84 and 85 above. Prostate
cancer data was identified and collected in the
population based cancer registries through the 18
Pathology Laboratories (where male populations
referred to these centers) and using a structured
questionnaire, trained personnel conducted in-person
interviews to collect information on prostate cancer. in
the Golestan province. These were then sent to the
Cancer Registry Office of the province and to the
cancer registry unit in the Health Deputy. Age-specific
rates, annual age-adjusted rates (ASRs) per 100,000
person-years were calculated using the direct methods
of standardization to the world population. The data
were summarized in a data sheet and coded using the
ICD-O. The data were recorded at different levels due
to a need for correct registration. This has been done by
iarccrgtools-203 software, because it could control the
probable problems due to registration at different level.
RESULTS
A total of 409 males cancer registry from all sites
were captured during the one year period, 2004. From
this 28 cases were prostate cancer .Prostate cancer
incidence rates vary by age .The highest prostate cancer
incidence among males in Golestan province was in
age 80-84 ( ASR: 215.87/100,000).The prostate cancer
incidence according to age specific was as follow: in
ages : in ages 0-4, 5-9, 10-14 , 15-19 , 20-24, 25-29,
30-34 , 35-39 , 40-44 and 45-49 no prostate cancer
incidence(ASR: 0.00/100,000), in age 50-54 (ASR:
5.18/100,000), in age 55-59 no prostate cancer
incidence (ASR: 0.00/100,000), in age 60-64
(ASR:10.62/100,000), in age 65-69 (ASR:
18.31/100,000), in age 70-74 (ASR: 107.32/100,000) in
age 75-79 (ASR: 70.96/100,000), in age 80-84 ( ASR:
215.87/100,000) and in age above 85 no prostate cancer
incidence (ASR: 0.00/100,000). The incidence of
prostate cancer in age 80-84 has risen sharply and in
age 50-54 incidence of prostate cancer was the lowest
(ASR: 5.18/100,000). All diagnosed prostate cancer
was adenocarcinoma.
DISCUSSION
This study presents data and discusses age specific
prostate cancer incidence of the numbers of people
diagnosed with cancer. The findings of this study
showed that prostate cancer is one of the most common
cancers in the Golestan province among males. The
registry showed that the annual ASR for prostate cancer
was 5.17 per 100000 populations in Golestan province.
Prostate cancer is a disease predominantly affecting
elderly men, and, despite the widespread use of PSA
(prostate specific antigen) testing in many countries, the
number of deaths from prostate cancer has increased.
Compared with most cancers, prostate cancer tends to
grow slowly. The prostate cancer is the fifth most
common cancer in the world and the second most
common in men (19% in developed countries and 5.3%
in developing countries). Three-quarters of all cases are
in men aged 65 or more [16]. Comparison of the ASR
for prostate cancer (age specific) among males in
Golestan province with those of prostate cancer
worldwide show that the Golestan province is also a
risk areas like other places in the world. we found that
the incidence of prostate cancer rises from age 50 years
old (ASR: 5.18/100,000) and is highest in 80-84 years
old (ASR: 215.87/100,000). Hsing et al. [6] reviewed
data on international trends in prostate cancer incidence
and mortality. In the United States, they observed the
largest increases in incidence in high-risk countries, 
especially in younger men. This is probably partly the
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effect of increasing detection of prostate cancer due to
use of PSA (prostate specific antigen). But there were
also large increases in low-risk countries between 1975 
and 1990: 104% in Singapore, China; 84% in Miyagi,
Japan; 55% in Hong Kong; and 44% in Shanghai,
China. Some of this may be due to greater awareness of
the disease, and diagnosis of small and latent cancers.
The early diagnosis of prostate cancer maybe effective
to prevent the progress of this cancer. A number of risk
factors have been identified for prostate cancer. The
most important risk factors are age and risk increases
with age. Very few cases are registered in men under 50
and more than 60% of cases occur in men over 70 years
old. The largest number of cases is diagnosed in those
aged 70–79[17-20]. After controlling for age, the greatest 
increase in risk has generally been associated with a
family history of prostate cancer. Risk increases two to
three times for men with a family history of prostate
cancer in a first-degree relative [11]. The high rates of
prostate cancer have been associated with the high
[21-22]intake of animal fat . Clinicians should follow
recommended screening guidelines and encourage their
patients before age 50 and older (in this area) to have
annual PSA testing. The reason for high incidence
report in some countries is the use of PSA screening
test. On the other hand this report which is explained in
methodology is only focused on the registered cases
and this can influence in the reported prostate cancer.
Clinicians should also ensure that patients at high risk
for prostate cancer are identified and offered
appropriate referrals and treatment. Continued research
is needed on the causes, prevention, and treatment of
prostate cancer. In this area the incidence of prostate
cancer is started from age 50 years old onward. The age
specific prostate cancer maybe is one of the main cause
of cancer deaths in Golestan province. According to
this information Golestan province harbor a rather
incidence for prostate cancer (age specific), comparable
to the lower incidence reported in the world.
CONCLUSION
For the present time it can be said that prostate
cancer in males appear to be one of the most prevalent
and serious type of cancer in Golestan province and is
rising with ageing. Thoughtfully designed
epidemiological and clinical studies are pivotal to
unravel the details of why and how these are happening
and help to plan what should be done to combat
effectively with these still deadly diseases. Therefore,
further studies to look for the etiology and possible risk
factors seem logical.
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